 | The topic of this article may not meet Wikipedia's general notability guideline. (February 2024) |
 | This article needs additional citations for verification. (February 2024) |
Native name | 台灣浩鼎生技股份有限公司 |
|---|---|
| Company type | Public |
| TWSE: 4174(TPEx) | |
| Industry | Pharmaceuticals |
| Founded | 2002 |
| Headquarters | 19F., No.3, Yuanqu st., Nangang, Taipei, Taiwan |
Key people | Kung-Yee Liang (Chairman) |
| Website | www.obipharma.com |
![[icon]](view_image.php?q=OBI_Pharma,_Inc.&sq=Qlik&lang=&file=File:Wiki_letter_w_cropped.svg){kind=small} | This section needs expansion. You can help by adding to it. (February 2020) |
OBI Pharma, Inc. (Chinese: 台灣浩鼎生技股份有限公司) (TWSE: 4174) is a bio-pharmaceutical company, based in Nangang District, Taipei, Taiwan.[1][2]
In 2018 it announced that its drug, OBI-3424, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC).[3]
- ^ "OBI Pharma signs cancer drug deal with HK's Odeon - Taipei Times". www.taipeitimes.com. 2022-02-24. Retrieved 2024-04-19.
- ^ "Odeon Therapeutics acquires China rights to two cancer therapy candidates from Obi Pharma in $200M deal | BioWorld". www.bioworld.com. Retrieved 2024-04-19.
- ^ "FDA grants ODD to OBI Pharma's lead investigational drug candidate". www.biospectrumasia.com. Retrieved 2024-04-19.